Stephen Finn
Identifying non-coding RNA repertoires of aggressive prostate cancer Genetic information flows from genes on DNA as follows: gene (DNA)?RNA?protein. RNAs, which are the products of DNA, either give rise to...Read More
Sarah Holt
Dr. Holt earned a BA in Biology from Skidmore College, an MS in Public Health from the University of Colorado and a PhD in Epidemiology from the University of Washington....Read More
Junjie Feng
Systematic identification of genetic variants within AR binding sites that are associated with altered AR signaling and prostate cancer Androgen Receptor (AR) mediates the action of the male hormones, androgens...Read More
Andrea Harzstark
Dr. Harzstark earned a BS degree in Biological Sciences and an MD degree from Stanford University. She is currently a Fellow in Hematology and Oncology at UCSF. Immunotherapy offers the...Read More
Dimple Chakravarty
Nanotargeting Estrogen Receptor regulated Long Non Coding RNA in prostate cancer progression Androgens and Androgen Receptor (AR) fuel prostate cancer. Therefore, androgen deprivation therapy (ADT) is usually the preferred treatment...Read More
Airi Harui
Dr. Harui earned a BS in Pharmaceutical Sciences at University of Kobegakuin in Kobe, Japan and her MSc in Pharmaceutical Sciences from the University of Osaka. She earned her PhD...Read More
Thomas Guzzo
Dr. Guzzo earned a BS in Biology from Ursinus College and an MD from Temple University School of Medicine. He is currently a Urologic Oncology Fellow and clinical instructor at...Read More
Jeremy Durack
Prostate cancer diagnosis and precision medicine treatment decisions currently rely on results from invasive biopsy procedures. Current biopsy methods do not ensure that the quality of the sample collected is...Read More
Shalini S. Yadav
Growing clinical evidence suggests that a majority of cancer patients present with “intratumoral heterogeneity”—that is, not only do tumors at one site in their body differ from those at another,...Read More